마이크로 RNA 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of microRNA Market

The global microRNA market size was valued at USD 2.02 billion in 2025 and is projected to increase from USD 2.32 billion in 2026 to USD 7.00 billion by 2034, registering a CAGR of 14.80% during 2026-2034. North America dominated the market with a 45.22% share in 2025. The market is expanding as microRNA technologies become increasingly important in molecular research, disease diagnostics, biomarker discovery, and therapeutic development for chronic diseases.

MicroRNAs are small non-coding RNA molecules that regulate gene expression and are increasingly studied for their potential applications in cancer, cardiovascular disorders, neurological diseases, liver diseases, infectious diseases, and metabolic conditions. The growing number of clinical trials, advances in miRNA profiling, and development of miRNA inhibitors and mimics are supporting market growth. Increasing investments in molecular diagnostics and biotechnology research are also creating opportunities for market participants.

Market Definition and Scope

The microRNA market includes products, instruments, kits, reagents, technologies, and related solutions used for microRNA research, detection, profiling, isolation, purification, diagnostics, and therapeutic development. The market serves healthcare facilities, pharmaceutical and biotechnology companies, research institutions, and other organizations involved in molecular biology and medical research.

Market Dynamics

Drivers

Increasing clinical trials targeting chronic diseases is a major factor supporting microRNA market growth. Researchers are investigating microRNAs as biomarkers, therapeutic targets, and regulators of disease processes. Their potential role in cancer diagnosis and treatment, drug resistance, and personalized medicine is encouraging pharmaceutical companies and research organizations to expand their development programs.

Trends

Technological advancements in microRNA expression profiling, target-gene identification, sequencing, and validation are emerging as important market trends. New instruments, assays, and analytical platforms are improving the efficiency of miRNA research. The increasing use of molecular diagnostics and advanced research technologies is also expanding the application scope of microRNA solutions.

Restraints

Safety and toxicity concerns associated with miRNA-based therapeutics may restrict market development. Clinical development can face challenges related to immune reactions, adverse effects, delivery mechanisms, and therapeutic specificity. These concerns may increase development costs and contribute to delays or discontinuation of certain clinical programs.

Impact of COVID-19

The COVID-19 pandemic affected laboratory research, clinical trials, healthcare operations, and global supply chains. Restrictions on laboratory activities and difficulties in patient recruitment disrupted some research programs. At the same time, the pandemic increased interest in molecular biology, biomarkers, genetic analysis, and advanced diagnostic technologies, supporting longer-term research activity in the microRNA field.

Segmentation Analysis

By Product

The market is segmented into instruments and kits & reagents. The instruments segment is projected to experience significant growth during the forecast period because of increasing research activity and demand for advanced technologies used in microRNA profiling and analysis. Kits and reagents remain important because they are widely required for sample preparation, detection, isolation, and molecular analysis.

By Application

The major applications include disease diagnostics and isolation & purification. Disease diagnostics accounted for the largest market share, supported by the growing prevalence of chronic diseases and increasing demand for molecular diagnostic approaches. Isolation and purification are also expected to experience strong growth as researchers require efficient methods for extracting miRNA and extracellular vesicle RNA.

By End User

The market is divided into healthcare facilities and pharmaceutical & biotechnology companies. Healthcare facilities represented a major end-user segment because of increasing collaborations involving hospitals, diagnostic organizations, and research institutions. Pharmaceutical and biotechnology companies are expected to expand their participation as investments in miRNA-based therapeutics, diagnostics, and research increase.

Regional Insights

North America

North America dominated the microRNA market with a 45.22% share in 2025. The region benefits from extensive clinical research, increasing therapeutic development, advanced molecular diagnostic capabilities, and product launches. The U.S. remains an important market because of its established biotechnology and pharmaceutical research infrastructure.

Europe

Europe is projected to remain a significant regional market and is expected to grow at a CAGR of 13.7% during the forecast period. Increasing research funding, molecular diagnostics development, and biotechnology activity are supporting market expansion across countries including Germany and other major European markets.

Asia Pacific

Asia Pacific is expected to witness strong growth because of a large patient population, increasing healthcare investments, growing adoption of miRNA technologies, and expanding research capabilities. China is projected to register a CAGR of 14.20% during the forecast period, while Japan is expected to reach USD 17.1 million in 2025 according to the provided report data.

Competitive Landscape

The microRNA market features prominent companies including QIAGEN N.V., Thermo Fisher Scientific, BioVendor, Takara Bio Inc., Merck KGaA, NanoString Technologies, Heim Biotek, and GeneCopoeia. Companies are focusing on strategic partnerships, product development, molecular profiling technologies, research solutions, and commercialization activities to strengthen their market presence.

Report Coverage

The microRNA market report covers market size and forecast, product types, applications, end users, regional analysis, market trends, growth drivers, restraints, competitive developments, and key industry participants. It also examines technological advancements and factors influencing the adoption of microRNA-based research, diagnostics, and therapeutic solutions.

Conclusion

The global microRNA market is positioned for substantial expansion, increasing from USD 2.02 billion in 2025 to USD 2.32 billion in 2026 and reaching USD 7.00 billion by 2034 at a 14.80% CAGR. Growing clinical research, advances in molecular diagnostics, increasing chronic disease burden, and expanding pharmaceutical and biotechnology applications are supporting market development. North America remains the leading regional market, while Asia Pacific presents strong growth opportunities. Continued technological innovation and research into safer and more effective miRNA-based diagnostic and therapeutic applications are expected to shape the market through 2034.

Unit Value (USD million)

Segmentation By Product

• Instruments
• Kits & Reagents

By Application

• Isolation & Purification
• Detection & Quantification
• Disease Diagnostics
• Others

By End-User

• Pharma & Biotech Companies
• Academic & Research Institutes
• Healthcare Facilities
• Others

By Geography

• North America (By Product, By Application, By End User, and by Country)
• Europe (By Product, By Application, By End User, and by Country)
• Asia-Pacific (By Product, By Application, By End User, and by Country)
• Rest of the World (By Product, By Application, By End User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Overview of Clinical Trials - Key Candidates, Key Companies
  • 4.1.1. Clinical Trials: Potential Candidates, miRNA's as Therapeutic Agents
  • 4.1.2. Clinical Trials: Potential Candidates, miRNA's as Biomarkers & Diagnostics
• 4.2. Regulatory Scenario - miRNA Diagnostic & Therapeutic Products
• 4.3. Impact of Covid-19 on the Market
• 4.4. Key Developments, Mergers, Acquisitions, etc.

5. Global MicroRNA Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Instruments
  • 5.2.2. Kits & Reagents
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Isolation & Purification
  • 5.3.2. Detection & Quantification
  • 5.3.3. Disease Diagnostics
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharma & Biotech Companies
  • 5.4.2. Academic & Research Institutes
  • 5.4.3. Healthcare Facilities
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America MicroRNA Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Instruments
  • 6.2.2. Kits & Reagents
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Isolation & Purification
  • 6.3.2. Detection & Quantification
  • 6.3.3. Disease Diagnostics
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharma & Biotech Companies
  • 6.4.2. Academic & Research Institutes
  • 6.4.3. Healthcare Facilities
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe MicroRNA Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Instruments
  • 7.2.2. Kits & Reagents
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Isolation & Purification
  • 7.3.2. Detection & Quantification
  • 7.3.3. Disease Diagnostics
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharma & Biotech Companies
  • 7.4.2. Academic & Research Institutes
  • 7.4.3. Healthcare Facilities
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific MicroRNA Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Instruments
  • 8.2.2. Kits & Reagents
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Isolation & Purification
  • 8.3.2. Detection & Quantification
  • 8.3.3. Disease Diagnostics
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharma & Biotech Companies
  • 8.4.2. Academic & Research Institutes
  • 8.4.3. Healthcare Facilities
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Rest of the World MicroRNA Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Instruments
  • 9.2.2. Kits & Reagents
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Isolation & Purification
  • 9.3.2. Detection & Quantification
  • 9.3.3. Disease Diagnostics
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharma & Biotech Companies
  • 9.4.2. Academic & Research Institutes
  • 9.4.3. Healthcare Facilities
  • 9.4.4. Others

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2025)
• 10.3. Competition Dashboard
• 10.4. Comparative Analysis - Major Players
• 10.5. Company Profiles
  • 10.5.1. QIAGEN N.V.
    • 10.5.1.1. Overview,
    • 10.5.1.2. Products,
    • 10.5.1.3. SWOT analysis,
    • 10.5.1.4. Recent developments,
    • 10.5.1.5. strategies,
    • 10.5.1.6. financials (based on availability)
  • 10.5.2. Thermo Fisher Scientific, Inc
    • 10.5.2.1. Overview,
    • 10.5.2.2. Products,
    • 10.5.2.3. SWOT analysis,
    • 10.5.2.4. Recent developments,
    • 10.5.2.5. strategies,
    • 10.5.2.6. financials (based on availability)
  • 10.5.3. Heim Biotek
    • 10.5.3.1. Overview,
    • 10.5.3.2. Products,
    • 10.5.3.3. SWOT analysis,
    • 10.5.3.4. Recent developments,
    • 10.5.3.5. strategies,
    • 10.5.3.6. financials (based on availability)
  • 10.5.4. BioVendor
    • 10.5.4.1. Overview,
    • 10.5.4.2. Products,
    • 10.5.4.3. SWOT analysis,
    • 10.5.4.4. Recent developments,
    • 10.5.4.5. strategies,
    • 10.5.4.6. financials (based on availability)
  • 10.5.5. Takara Bio Inc.
    • 10.5.5.1. Overview,
    • 10.5.5.2. Products,
    • 10.5.5.3. SWOT analysis,
    • 10.5.5.4. Recent developments,
    • 10.5.5.5. strategies,
    • 10.5.5.6. financials (based on availability)
  • 10.5.6. Merck KGaA
    • 10.5.6.1. Overview,
    • 10.5.6.2. Products,
    • 10.5.6.3. SWOT analysis,
    • 10.5.6.4. Recent developments,
    • 10.5.6.5. strategies,
    • 10.5.6.6. financials (based on availability)
  • 10.5.7. GeneCopoeia, Inc.
    • 10.5.7.1. Overview,
    • 10.5.7.2. Products,
    • 10.5.7.3. SWOT analysis,
    • 10.5.7.4. Recent developments,
    • 10.5.7.5. strategies,
    • 10.5.7.6. financials (based on availability)
  • 10.5.8. NanoString Technologies, Inc.
    • 10.5.8.1. Overview,
    • 10.5.8.2. Products,
    • 10.5.8.3. SWOT analysis,
    • 10.5.8.4. Recent developments,
    • 10.5.8.5. strategies,
    • 10.5.8.6. financials (based on availability)
  • 10.5.9. Others
    • 10.5.9.1. Overview,
    • 10.5.9.2. Products,
    • 10.5.9.3. SWOT analysis,
    • 10.5.9.4. Recent developments,
    • 10.5.9.5. strategies,
    • 10.5.9.6. financials (based on availability)

11. Strategic Recommendations